Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
April 18, 202419m 0s
Audio is streamed directly from the publisher (prfx.byspotify.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients with ITP or other autoimmune cytopenias, which ones will go on to develop systemic lupus?
Featured Articles:
- CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis
- Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation
- Antinuclear antibody–associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus
Topics
hematologyoncologymedicalmedical researchlymphomaleukemiaCAR Tred cells